

Table S1. Summary of previously reported cases of MTX-associated lymphoproliferative disorders with cutaneous manifestations

Author	Age/sex	Underlying disease	Prior treatment	Cutaneous manifestation	Extracutaneous involvement	Pathology	EBV	Discontinue of drug	Treatment	Outcome
Kamel OW, et al. (1)	86/F	RA	MTX, PSL	Nodules	None	DLBCL	Positive	D/C MTX	None	CR
Viraben R, et al. (2)	58/M	Arthritis	MTX	Solitary nodule	None	BCL	Negative	D/C MTX	None	CR
Chai C, et al. (3)	38/F	DM	MTX, PSL	Solitary plaque	None	LPD (proliferation of atypical lymphocytes)	Positive	Continue MTX	Radiation	CR
Fam AG, et al. (4)	58/F	RA	MTX, PSL	Nodules	None	Oligoclonal large BCL	Positive	D/C MTX	None	CR
Tournadre A, et al. (5)	70/M	RA	MTX, PSL	Papules	None	CTCL	Positive	D/C MTX	None	CR
Tournadre A, et al. (6)	47/F	DM	MTX, PSL	Nodules	None	Polymorphic centroblastic BCL	Positive	D/C MTX	None	CR
Verma S, et al. (7)	75/F	RA	MTX, PSL	Nodules	Lungs	DLBCL	Positive	D/C MTX	Multiagent chemotherapy, acyclovir	CR
Maruani A, et al. (8)	70/F	RA	MTX	Nodules	None	LPD (proliferation of atypical B cells)	Positive	D/C MTX	None	CR
Clarke LE, et al. (9)	91/F	RA	MTX	Nodules	None	DLBCL	Negative	D/C MTX	None	CR
Nakashima C, et al. (10)	53/F	RA, SS	MTX, IFX	Indurated erythema	Lymph node, liver	DLBCL	Negative	D/C MTX, D/C R-CHOP	None	CR
Shimura C, et al. (11)	80/F	RA	MTX	Nodules	None	Diffuse polymorphic or Hodgkin lymphoma-like LPD	Positive	D/C MTX	None	CR
Pfisterhammer K, et al. (12)	67/F	RA	MTX	Erythematous patches, nodules	None	DLBCL	Negative	NR	R-CHOP	CR
Curry JL, et al. (13)	74/M	MF	MTX, PSL, AZA	Ulcerated plaque	Blood	LPD (proliferation of atypical B cells)	Positive	NR	NR	NR
Giard C, et al. (14)	71/F	DM	MTX, PSL	Ulcer	None	BCL	NR	D/C MTX	None	CR
Huwait H, et al. (15)	67/F	DM	MTX, PSL	Nodules	None	Composite lymphoma	Negative	NR	R-CVP	Persistent
Rausch T, et al. (16)	77/M	MF	MTX	Nodules	Lung, lymphnodes	DLBCL	Positive	D/C MTX	Rituximab	CR
Sakurai K, et al. (17)	73/F	RA	MTX	Nodules	Lungs, liver, spleen, kidneys	LPD (polymorphic atypical lymphocytic proliferation)	Positive	D/C MTX	None	CR
Case 1	63/F	DM, SS	MTX, PSL	Nodules	Lungs	DLBCL	Positive	D/C MTX	None	CR
Case 2	74/M	RA	MTX, PSL	Nodules, ulcer	None	DLBCL	Positive	D/C MTX	None	CR

LPD: lymphoproliferative disorder; BCL: B cell lymphoma; DLBCL: diffuse large B cell lymphoma; CTCL: cutaneous T cell lymphoma; RA: rheumatoid arthritis; MF: mycosis fungoides; SS: Sjögren's syndrome; DM: dermatomyositis; AZA: azathioprine; INF: infliximab; D/C: discontinuation; CR: complete remission; R-CHOP: rituximab, cyclophosphamide, doxorubicin, prednisolone; R-CVP: rituximab, cyclophosphamide, vincristine, prednisolone; NR: not reported.

SUPPLEMENTARY REFERENCES LIST

1. Kamel OW, van de Rijn M, Weiss LM, Del Zoppo GJ, Hench PK, Robbins BA, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. *N Engl J Med* 1993; 328: 1317–1321.
2. Viraben R, Brousse P, Lamant L. Reversible cutaneous lymphoma occurring during methotrexate therapy. *Br J Dermatol*. 1996; 135: 116–118.
3. Chai C, White WL, Shea CR, Prieto VG. Epstein-Barr virus-associated lymphoproliferative-disorders primarily involving the skin. *J Cutan Pathol*. 1999; 26: 242–247.
4. Fam AG, Perez-Ordóñez B, Imrie K. Primary cutaneous B cell lymphoma during methotrexate therapy for rheumatoid arthritis. *J Rheumatol*. 2000; 27: 1546–1549.
5. Tournadre A, D'Incan M, Dubost JJ, Franck F, Dechelotte P, Souteyrand P, et al. Cutaneous lymphoma associated with Epstein-Barr virus infection in 2 patients treated with methotrexate. *Mayo Clin Proc* 2001; 76: 845–848.
6. Verma S, Frambach GE, Seilstad KH, Nuovo G, Porcu P, Magro CM. Epstein-Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin. *J Cutan Pathol*. 2005; 32: 474–483.
7. Maruani A, Wierzbicka E, Machet MC, Abdallah-Lotf M, de Muret A, Machet L. Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis. *J Am Acad Dermatol*. 2007; 57 (5 Suppl): S69–S71.
8. Clarke LE, Junkins-Hopkins J, Seykora JT, Adler DJ, Elenitsas R. Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. *J Am Acad Dermatol*. 2007; 56: 686–690.
9. Nakashima C, Tanioka M, Takahashi K, Miyachi Y. Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate. *Clin Exp Dermatol* 2008; 33: 437–439.
10. Shimura C, Satoh T, Takayama K, Yokozeki H. Methotrexate-related lymphoproliferative disorder with extensive vascular involvement in a patient with rheumatoid arthritis. *J Am Acad Dermatol*. 2009; 61: 126–129.
11. Pfistershammer K, Petzelbauer P, Stingl G, Mastan P, Chott A, Jager U, et al. Methotrexate-induced primary cutaneous diffuse large B-cell lymphoma with an 'angiocentric' histological morphology. *Clin Exp Dermatol*. 2010; 35: 59–62.
12. Curry JL, Prieto VG, Jones DM, Vega F, Duvic M, Diwan AH. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sezary syndrome. *J Cutan Pathol* 2011; 38: 295–297.
13. Giard C, Avenel-Audran M, Croue A, Verret JL, Martin L. Primary cutaneous Epstein-Barr virus-associated B-cell lymphoma arising at the site of subcutaneous injections of methotrexate. *J Clin Oncol*. 2010; 28: e717-e718.
14. Huwait H, Wang B, Shustik C, Michel RP. Composite cutaneous lymphoma in a patient with rheumatoid arthritis treated with methotrexate. *Am J Dermatopathol* 2010; 32: 65–70.
15. Rausch T, Cairolì A, Benhattar J, Spring P, Hohl D, de Leval L. EBV+ cutaneous B-cell lymphoproliferation of the leg in an elderly patient with mycosis fungoides and methotrexate treatment. *APMIS*. 2013; 121: 79–84.
16. Sakurai K, Murata T, Yamamoto M, Kore-Eda S. Methotrexate-associated lymphoproliferative disorder diagnosed by skin biopsy in a patient with multiple systemic nodules. *Eur J Dermatol*. 2013; 23: 723–724.